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Background: There is limited information about any association between the onset of atrial fibrillation (AF) and the
presence of valvular disease.
Methods: We retrospectively examined 940 patients in sinus rhythm, examined by echocardiography in 1996.
During 11 years of follow-up, we assessed the incidence of AF and outcome defined as valvular surgery or death, in
relation to baseline valvular function. AS (aortic stenosis) severity at baseline examination was assessed using peak
transaortic valve pressure gradient.
Results: In univariate analysis, the risk of developing AF was related to AS (significant AS versus no significant AS;
hazard ratio (HR) 3.73, 95% confidence interval (CI) 2.39-5.61, p<0.0001) and mitral regurgitation (MR) (significant MR
versus no significant MR; HR 2.52, 95% CI 1.77-3.51, p<0.0001). Also the risk of valvular surgery or death was related
to AS (HR 3.90, 95% CI 3.09-4.88, p<0.0001) and MR (HR 2.07, 95% CI 1.67-2.53, p<0.0001). In multivariate analyses,
adjusting for sex, age, other valvular abnormalities, left ventricular ejection fraction and left atrial size − AS was
independently related to both endpoints, whereas MR was not independently related to either endpoint.
Conclusions: AS, but not MR, was independently predictive of development of AF and combined valvular surgery
or death. In patients with combined AS and MR, the grade of AS, more than the grade of MR, determined the risk
of AF and combination of valvular surgery or death. Further studies using contemporary echocardiographic
quantification of aortic stenosis are warranted to confirm these retrospective data based on peak transaortic valve
pressure gradient.
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Valvular heart disease is a cause of atrial fibrillation (AF)
[1,2]. Mitral valve disease, especially mitral regurgitation
(MR), is the most common cause and the most well-
known cause [3-5]. However, there is little information
about the incidence of AF in patients with aortic valve
disease, with or without MR.
We aimed to examine whether aortic stenosis (AS)
and MR were associated with AF and long-term out-
come in a large group of patients undergoing clinically
motivated echocardiography examination. We designed
the study to address the following hypotheses: (1) both* Correspondence: veronica.widgren@gmail.com
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reproduction in any medium, provided the orAS and MR increase the risk of developing AF and
valvular surgery or death, (2) AS in combination with
MR is associated with the highest incidence of AF and
valvular surgery or death, and (3) AS is at least equally
important as MR for the risk of developing AF and
valvular surgery or death, among individuals with com-
bined AS and MR.Methods
Study population and design
All patients (n=2752) undergoing echocardiography dur-
ing 1996 at the Department of Clinical Physiology,
Malmö University Hospital, were assessed for possible
enrolment in this retrospective cohort study (Figure 1).
For patients with multiple echocardiograms in 1996, thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.




116 (4.2%) patients because 
of lack of archive records
644 (23.4%) patients 
because of exclusion criteria
650 (23.6%) patients with 
incomplete assessment of 
valvular function.
1342 patients (48.8%) with adequate assessment of 
valvular function
Group 1
802 patients with any clinically important valvular 
lesion
Group 2
540 patients with at the most mild MI and/or TI, no other 
valvular lesion
270 patients were randomly selected (50%)
115 (12.7%) 
patients with AF 
before the baseline 
EKG
excluded excluded 17 (2.9%) patients 
with AF before the 
baseline EKG
687 with any clinically important 
valvular lesion and SR
253 patients with minimal
MI and/or TI and SR
940 with adequate assessment of valvular function 
and SR. (Study population)
186 patients with onset of AF during the study
Figure 1 Enrolment and outcomes. SR, sinus rhythm; AF, atrial fibrillation; ECG, electrocardiogram; AS, aortic stenosis; AR, aortic regurgitation;
MR, mitral regurgitation; TR, tricuspid regurgitation.
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ation. The list of patients was cross- referenced with the
hospital electronic patient record system, the diagnostic
codes database, and the electrocardiography (ECG) data-
base, to obtain relevant clinical information.
Exclusion criteria were: any documented episode of
AF or atrial flutter before or at the time of the baseline
echocardiogram, left-sided subvalvular outflow tract ob-
struction, congenital heart defects, aortic coarctation,
and any type of valvular surgery, incomplete social se-
curity number, age less than 18 years and echocardio-
graphic examination with poor image quality. Targeted
examinations, such as control of pericardial effusion or
examinations restricted to the assessment of left ven-
tricular (LV) function only, as well as reports with in-
complete echocardiographic data, were also excluded.
In addition, 650 patients with no specific report of
valvular function were excluded from the study, since it
could not be precluded that this might have been due to
a lack of adequate assessment of valvular function. After
this initial exclusion, 1342 subjects (726 women, 54%,
aged 50–82 years) remained.These patients were divided into two groups. Subjects
in Group 1 had at least one valve lesion of clinical im-
portance, defined as at least mild AS and/or aortic re-
gurgitation (AR), and/or more than mild MR and/or
tricuspid regurgitation (TR). No patient had any clinic-
ally relevant valvular lesion of any other kind. All sub-
jects in this group (802 subjects, 430 women, 54%, aged
56–84 years) were included in the analysis. Group 2
comprised 540 patients (296 women, 55%, aged 42–77
years) with normal aortic and pulmonary valve function
but with at the most mild mitral and/or tricuspid regur-
gitation. Half of these were randomly selected. After
thorough ECG database review, a further 115 patients
were excluded from Group 1 and 17 from Group 2 be-
cause of AF or atrial flutter before the baseline echocar-
diogram. The remaining 940 patients comprised the
study population.
Echocardiography
Patients underwent comprehensive, standardized trans-
thoracic two-dimensional echocardiography/Doppler eval-
uation during 1996, by experienced echocardiography
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using Sonos 2500 equipment (Philips, Andover, Mass.). LV
and left atrial (LA) dimensions were measured by 2D
guided M-mode [6]. Left ventricular ejection fraction
(LVEF) was assessed semi-quantitatively by 2-D visual esti-
mation [7] and expressed in percent [8]. Valvular regurgi-
tation was assessed semi-quantitatively by 2-D colour
Doppler visual estimation [9,10] and scored from 0
through 5: 0 = no regurgitation, 1 = mild, 2 = mild-
moderate, 3 = moderate, 4 = moderate-severe, 5 = severe.
Grades 3–5 were considered significant. AR pressure half
time was used in addition to visual assessment of AR jet
size. A pressure half time of >500 ms indicated mild AR,
500–200 ms moderate AR, and <200 ms indicated severe
AR. AS was evaluated quantitatively and scored as fol-
lows: 0 = no stenosis (calculated peak transaortic valve
pressure gradient <20 mm Hg), 1 = mild (pressure gradi-
ent 20–30 mm Hg), 2 = mild-moderate (pressure gradient
31–40 mm Hg), 3 = moderate (pressure gradient 41–50
mm Hg), 4 = moderate-severe (pressure gradient 51–60
mm Hg), 5 = severe (pressure gradient >60 mm Hg).
Grades 3–5 were considered significant. In addition, vel-
ocity time integral (VTI) ratio of the left ventricular out-
flow tract (LVOT) and aortic valve (AV) - (VTI LVOT/
VTI AV) and/or calculation of aortic valve area were
used if LV systolic function was reduced and/or the pres-
ence of AR.Clinical assessment and endpoints
All patients were followed-up from the baseline echocar-
diogram until the date of an endpoint or until the 1st of
September 2007. There were two endpoints: 1) the first
registered episode of AF (occurring before valve surgery
but after the baseline echocardiogram) and 2) death or
the first registered episode of heart valve surgery. AF
events were ascertained through thorough review of the
electronic patient record systems and all ECGs recordedTable 1 Baseline clinical and echocardiographic characteristic
All No AS AS
N, patients 940 838 102
Age, years 66.6±15.4 65.6±15.5 75.2±11.4
Sex (women), % 56 55 65
LA diameter, mm 40±7 40±7 41±6
LVEF, % 54±9 55±9 49±11
LV diameter, mm 53±8 53±8 50±7
AS, % 11
MR, % 16 15 20
TR, % 11 10 12
AR, % 11 9 29
AS-aortic stenosis grades 3–5; MR-mitral regurgitation grades 3–5; TR-tricuspid regu
ventricular; LVEF-left ventricular ejection fraction.after the baseline echocardiogram. No distinction was
made between paroxysmal, persistent or permanent AF.Statistical analysis
Continuous variables were expressed as mean ± SD and
between-group differences were assessed by the one-way
ANOVA test. Between-group differences in categorical
variables were tested with the χ2 test. Differences in
time-to-endpoint were compared using the log-rank test.
Between-group differences in the primary endpoints
were also assessed by univariable Cox Proportional
Hazards analyses initially, and then clinical (i.e. age and
gender) and echocardiographic (i.e. other valvular abnor-
malities, LVEF and LA size) variables were included in a
multivariable Cox Proportional Hazards Model with
stepwise backwards selection. Although the term “other
valvular abnormalities” in its true sense can mean any
valvular disorder, we used it in this study to describe
only the four most commonly clinically important valve
conditions – AS, AR, MR and TR. As a result of the
multivariable analysis, hazard ratios (HR) and 95 % con-
fidence intervals (CI) were calculated. P<0.05 denoted
statistical significance, except for the two co-primary
endpoints, for which p<0.025 was considered statistically
significant.Results
Baseline characteristics
The study population consisted of 940 subjects (528
women, 56%) aged 51–82 years (Table 1). Compared to
subjects without significant AS (n=838, 89%), subjects
with significant AS (n=102, 11%) were older and more
often women, and had lower LVEF and smaller LV diam-
eter. Compared to subjects without significant MR
(n=791, 84%), subjects with significant MR (n=149, 16%)
were older, had lower LVEF, and larger LV and LA
diameter.s
p-value No MR MR p-value
791 149
<0.0001 65.9±15.5 70.5±14.4 0.0008
0.0658 57 51 0.1661
0.0205 39±6 45±7 <0.0001
<0.0001 568±8 45±12 <0.0001
0.0062 52±7 59±10 <0.0001
10 13 0.2712
0.2712
0.6960 7 30 <0.0001
<0.0001 10 21 <0.0001
rgitation grades 3–5; AR-aortic regurgitation grades 3–5; LA-left atrium; LV-left
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Aortic stenosis
More patients with significant AS experienced AF
(n=27, 27%), compared to subjects without significant
AS (n=159, 19%): HR 3.73, 95% CI 2.39 – 5.61, p<0.0001
(Figure 2a). More patients with significant AS experi-
enced death or heart valve surgery (n=94, 92%), com-
pared to subjects without significant AS (n=449, 54%):
HR 3.90, 95% CI 3.09 – 4.88, p<0.0001 (Figure 2b). Me-
dian time to AF was not applicable since less than half
of the patients had AF during the follow-up time. The
median time to the composite endpoint was 2 years for
patients with significant AS and slightly more than 10
years for subjects without significant AS (p<0.0001).
Among patients with significant AS, the average annual
incidence of AF was 4.1%, and for the composite end-
point the annual incidence was 14.2%. Among subjectsAS
No AS
No AS   838 792 760 736 710 687
AS   102 84 80 79 75 75
Numbers of patients at risk
B
No AS  838 714 633 548 489 425
AS     102 50 31 16 12 8




Figure 2 Kaplan-Meier curves of event-free survival to AF.
(A) and the composite of valvular surgery or death (B), in patients
with (blue line) and without (red line) significant AS.without significant AS, the average annual incidence of
AF was 2.9%, and the annual incidence for the compos-
ite endpoint was 8.2%.
Mitral regurgitation
More patients with significant MR experienced AF
(n=43, 29%), compared to subjects without significant
MR (n=143, 18%): HR 2.52, 95% CI 1.77 – 3.51,
p<0.0001 (Figure 3a). More patients with significant MR
experienced the composite endpoint (n=113, 76%), com-
pared to subjects without significant MR (n=430, 54%):
HR 2.07, 95% CI 1.67 – 2.53, p<0.0001 (Figure 3b).
Median time to AF was not applicable since less than
half of the patients had AF during the follow-up. The
median time to the composite endpoint was 3.5 years
for patients with significant MR, and 9.9 years for sub-






Numbers of patients at risk
Numbers of patients at risk
No MR   791        751        721        698        677        656      
MR   149        125       119       117       108         106        
No MR  791       674        594        507        455        392
MR   149       90        70          57        46          41        
Figure 3 Kaplan-Meier estimates of event-free survival to AF.
(A) and the composite of valvular surgery or death (B), in patients
with (blue line) and without (red line) significant MR.
Widgren et al. BMC Cardiovascular Disorders 2012, 12:92 Page 5 of 8
http://www.biomedcentral.com/1471-2261/12/92with significant MR, the average annual incidence of AF
was 4.4%, whereas it was 11.7% for the composite end-
point. Among subjects without significant MR, the aver-
age annual incidence of AF was 2.8%, whereas it was
8.4% for the composite endpoint.
Relative importance of AS and MR
We divided patients into four groups: Group A, no sig-
nificant AS or MR; Group B, no significant AS but sig-
nificant MR; Group C, significant AS but no significant
MR; and Group D, both significant AS and MR.
The four-group comparison gave p<0.0001 for both
AF (Figure 4a) and the composite endpoint (Figure 4b).
Group D had the shortest median time to the composite
endpoint (1.6 years), Group C had the second shortest
(2.2 years) and Group A had the longest (11.1 years).
Median time to AF was not applicable.
In order to further investigate potential differences be-
tween groups we compaired groups pairwise. Comparing
Group C to Group A, HR was 4.75 (95% CI 2.89-7.49,A
AS, MR
Numbers of patients at risk
No AS, no MR 709      683       656      634 
No AS, MR   129      109      104      102 
AS, no MR         82        68       65       64
AS, MR            20        16        15          15
B
AS, MR
Numbers of patients at risk
No AS, no MR 709       631       566      492 
No AS, MR      129     83        67        56 
AS, no MR         82        43          28        15 
AS, MR            20         7           3         1 
Figure 4 Kaplan- Meier estimates of event-free survival to AF (A) and
analysis. Group A (red), Group B (green), Group C (blue) and Group D (orap<0.0001) for AF and 4.28 (95% CI 3.30–5.49, p<0.0001)
for the composite endpoint. Comparing Group B with
Group A, HR was 2.75 (95% CI 1.88-3.92, p<0.0001) for
AF and 2.15 (95% CI 1.70-2.69, p<0.0001) for the com-
posite endpoint. Comparing Group C with Group B gave
HR 1.46 (95% CI 0.83-2.50, p=0.1810) for AF and HR
1.78 (95% CI 1.30-2.41, p=0.0003) for the composite
endpoint.
Multivariable analysis
In the multivariable analysis, AS was consistently and in-
dependently related to both endpoints, whereas MR was
not independently related to either endpoint (Table 2).
Combined AS and MR, as a four-group variable, was in-
dependently related to both endpoints.
Discussion
Both AS and MR were related to AF, as well as to the
composite endpoint (valvular surgery or death). In the
univariate analysis, patients with significant AS hadNo AS, no MR
No AS, MR
AS, no MR
     617   596
        93       91
        60        60
         15        15 
No AS, no MR
No AS, MR
AS, no MR
      444        385          
        45         40       
        11         7   
         1         1
the composite of valvular surgery or death (B), in combined
nge).
Table 2 Hazard ratios for the endpoints in relation to various risk factors in multivariate analysis
AF, n=186 Composite endpoint
AS, MR AS+MR AS, MR AS+MR
HR CI p Value HR CI p Value HR CI p Value HR CI p Value
Age(year) 1.05 1.04-1.07 <0.0001 1.05 1.04-1.07 <0.0001 1.05 1.04-1.05 <0.0001 1.05 1.04-1.05 <0.0001
Sex(man) 1.30 1.09-1.55 0.0044 1.29 1.08-1.55 0.0054
AS 2.4 1.5-3.76 0.0002 2.24 1.75-2.84 <0.0001
MR
TR 1.44 1.11-1.84 0.0071 1.33 1.02-1.71 0.0338
AS+MR 0.0005 <0.0001
AR 0.59 0.33-0.97 0.0356 0.58 0.32-0.95 0.0306
LVEF 0.97 0.96-0.99 0.0013 0.98 0.96-100 0.0157 0.97 0.96-0.98 <0.0001 0.98 0.97-0.99 <0.0001
LA 1.09 1.07-1.11 <0.0001 1.09 1.06-1.11 <0.0001 1.02 1.01-1.03 <0.0047 1.02 1.00-1.03 0.0177
“AS, MR” indicates that AS and MR were analysed as individual variables. “AS+MR” indicates that AS and MR were analysed as a four-group variable. AS, aortic
stenosis; AR, aortic regurgitation; LA, left atrium; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; TR, tricuspid regurgitation.
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posite endpoint than those without significant AS. For
patients with significant MR, the risk of AF and the
composite endpoint was increased by 152% and 107%,
respectively, compared to patients without significant
MR.
We also performed multivariate analysis with adjust-
ment for age, sex, other valvular abnormalities, LVEF
and LA diameter. Notably, AS was independently related
to both endpoints, whereas MR was not independently
related to either endpoint in this analysis. Age, AS,
LVEF, LA and “AS+MR” as a four-group variable were
independently related to both endpoints in the multi-
variable analysis. Sex and TR were independently related
only to the composite endpoint, while there was still a
significant association between AR and AF. MR was not
related to either endpoint.
Our results suggest pathophysiological difference be-
tween AS and MR in AF development. It had been
shown that MR causes structural changes in LA includ-
ing dilatation, myofibril hypertrophy and fibrosis [11].
The atrial refractory period shortens as the atrium
dilates and the vulnerability to AF increases [12,13]. LA
size is a well-known powerful independent predictor of
AF [14-16]. Subjects with significant MR usually have
dilated LA due to volume overload. Indeed, in the
present study they had on average 6.3 mm larger LA size
than subjects without significant MR.
What do we know about LA size in patients with AS?
Dalsgaard et al. have shown that the degree of valvular
AS is an independent predictor of LA enlargement [17].
LV pressure overload causes compensatory concentric
LV hypertrophy [18], which leads to both LA pressure
overload and enlargement [17]. In our study individuals
with significant AS only had 1.5 mm larger LA diameter
than subjects without significant AS. This indicates that
AF in subjects with significant AS not only precipitatedby increased LA size, but rather by pressure overload
with subsequent LA structural remodeling.
There is a strong and extensive evidence of atrial fi-
brosis being a key player in the development and persist-
ence of AF [19,20]. Li and colleagues have shown that
atrial fibrosis causes localized regions of conduction
slowing, increasing conduction heterogeneity and
thereby providing an AF substrate [21]. Very recently it
has been demonstrated that mast cells can infiltrate the
atrium of pressure-overloaded mice and contribute to
the pathogenesis of atrial fibrosis and AF susceptibility
[22].
AS and MR are often seen together in clinical practice.
MR has been reported to be present in up to 70% of
patients with symptomatic severe AS [23,24]. The
present study clearly shows that, among patients with
combined AS and MR, the risk for valvular surgery or
death was mostly influenced by the AS. However, AS
and MR were nearly equally important for the risk of
AF alone. Subjects with combined AS and MR seem
to have the highest risk for both AF and the compos-
ite endpoint.
The presence of AF in patients with aortic valve dis-
ease is a poor prognostic sign, associated with consider-
able increase in morbidity and mortality. Bergeron et al.
[25] reported a 75% one-year mortality following the
onset of AF in patients with AS that exceeds 50% one-
year mortality following the onset of heart failure.
According to the latest American [26] and European
[27] guidelines for aortic valve replacement, patients
with asymptomatic severe AS and preserved LV systolic
function [28] should be managed by “watchful waiting”
with close clinical follow-up. While these asymptomatic
patients are followed-up, the pathophysiological changes
in the LV lead to the structural, functional and electro-
physiological abnormalities in the LA, culminating in
the development of AF [29]. In patients with severe AS,
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ation [18] and dramatically worsened prognosis [25].
According to current guidelines, with onset of symp-
toms, surgery may be considered in these patients. How-
ever, these patients are likely to have enlarged and
structurally abnormal LA. AF and its hazards are diffi-
cult to control once established and, therefore, a pre-
ventive approach to the problem may be preferable [2].
Possibly, aortic valve replacement might be justified in
some of these patients even at an asymptomatic stage.
This approach can perhaps be more easily accepted with
the development of new, less invasive methods. This
should be further investigated.Study limitations
This study has potential limitations, besides those caused
by its retrospective nature. The major limitations include
the absence of some potentially important clinical patient
data (e.g. history of hypertension, ischemic heart disease,
hyperthyroidism or detailed medication list). We had no
access to this information at the time of the baseline
examination 1996, because the hospital electronic patient
record system was established a few years later. There-
fore, adjustment for these factors was not possible.
Due to the retrospective nature of the study, the
method for AF detection in our study was based on the
presence of AF on clinically motivated ECG which can
obviously underestimate the true number of patients
with paroxysmal form of arrhythmia and could have
affected results if dedicated AF screening would had
been used.
Finally, differences between echocardiography guide-
lines in force today and practice that existed at the time
of baseline examination 1996 pose another limitation
that needs to be considered while interpreting our find-
ings. AS severity at baseline examination was assessed
using mainly peak transaortic valve pressure gradient,
which can be affected by other heamodynamic para-
meters such as the changes in cardiac output or preload
state. Information on AS jet velocity, mean transaortic
gradient or valve area, which are the fundametnals of AS
grading today [30] was not available for all subjects and
reevaluation of source historical image data not possible.
In regard to LVEF, the practice at the time was to rely
on visual estimation of LVEF, which may be considered
not as robust as quantification techniques used today
[31]. It has, however, been suggested that visual estima-
tion of LVEF is basically as accurate as LVEF estimation
by Simpson's biplane method of disc when compared to
a gold standard method [8]. Also, it would have made
the data more robust if only one observer had performed
grading of echocardiography, findings, which however
was not possible due to the nature of the investigation.Conclusion
During 11 years of follow-up of elderly patients, AS, but
not MR, was independently related to AF and combined
valvular surgery or death, irrespective of adjustment for
age, sex, other valvular disease, LVEF and LA diameter.
In addition, AS was more important than MR for the
risk of combined valvular surgery or death, whereas AS
and MR were about equally important for the risk of
developing AF. To the best of our knowledge, this is the
first study assessing the importance of AS and combined
lesions of AS and MR to the development of AF. How-
ever, further studies using contemporary echocardio-
graphic quantification of aortic stenosis are warranted to
confirm these retrospective data based on peak transaor-
tic valve pressure gradient.
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